The U.S. Food and Drug Administration has approved bemotrizinol as the first new sunscreen active ingredient since 1999. This ingredient, already used in sunscreens around the world, offers broad-spectrum protection against both UVA and UVB rays. A skin scientist explains that bemotrizinol works by absorbing ultraviolet light and converting it into harmless heat, providing more stable and longer lasting protection than many older ingredients.

Key takeaways

  • The FDA approved bemotrizinol, the first new sunscreen active ingredient in over 25 years.
  • Bemotrizinol provides broad-spectrum protection against UVA and UVB rays.
  • The ingredient absorbs UV light and converts it into heat, reducing skin damage.
  • It is already used in sunscreens sold in Europe, Asia, and other regions.
  • Experts say it offers more stable and longer lasting protection than older ingredients.

What is bemotrizinol and how does it work?

Bemotrizinol is a chemical sunscreen agent that absorbs ultraviolet radiation. According to the skin scientist interviewed by Medical Xpress, the molecule is designed to capture UV light across a wide range of wavelengths. Once absorbed, the energy is released as heat, preventing it from damaging skin cells. This mechanism is similar to other chemical sunscreens, but bemotrizinol is more stable and does not break down as quickly when exposed to sunlight.

The ingredient is particularly effective at blocking UVA rays, which are associated with skin aging and some skin cancers, as well as UVB rays, which cause sunburn. Most older sunscreen ingredients are less effective against the full UVA spectrum.

Why has it taken so long for a new ingredient to be approved?

The FDA has not approved a new sunscreen active ingredient since 1999 due to a combination of regulatory hurdles and testing requirements. The agency requires extensive safety and efficacy data, including studies on absorption through the skin and potential health effects. Many manufacturers have been reluctant to invest in the costly approval process for the U.S. market.

Bemotrizinol has been used for years in sunscreens sold in Europe, Asia, Australia, and other regions. The recent approval follows updated FDA guidance and a push from dermatologists and consumer groups for more modern sunscreen options. The approval is seen as a step toward bringing U.S. sunscreen regulations in line with global standards.

What does this mean for consumers?

Consumers in the U.S. will soon have access to sunscreens containing bemotrizinol. These products are expected to offer better protection, especially against UVA rays, and may be more pleasant to use because the ingredient is less likely to leave a white cast on the skin. However, the skin scientist notes that no sunscreen blocks 100 percent of UV rays, and proper application and reapplication remain important.

The approval does not mean that older sunscreen ingredients are unsafe or ineffective. It simply adds a new option that may be more convenient and provide broader protection. Sunscreens with bemotrizinol are expected to appear on store shelves within the next year.

Frequently Asked Questions

Is bemotrizinol safe?

According to the FDA and the skin scientist, bemotrizinol has been extensively tested and is considered safe for use in sunscreens. It has been used in other countries for many years without significant safety concerns. The FDA reviewed data on skin absorption, toxicity, and potential health effects before approving it.

Will bemotrizinol replace other sunscreen ingredients?

No, bemotrizinol is not expected to replace existing sunscreen ingredients entirely. It will likely be used in combination with other filters to create broad-spectrum products. Many sunscreens already contain multiple active ingredients to cover different parts of the UV spectrum.

When will sunscreens with bemotrizinol be available in stores?

Manufacturers will need time to reformulate products and meet labeling requirements. The skin scientist estimates that sunscreens containing bemotrizinol could be available in the U.S. within the next 12 months. Until then, consumers should continue using existing broad-spectrum sunscreens with SPF 30 or higher.

This is an original report by Vital Signs Today, informed by reporting from Medical Xpress. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.